Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Khalid Mezzi
Cardiovascular Events During Carfilzomib Therapy for Relapsed Myeloma: Practical Management Aspects From Two Case Studies
Hematology
Hematology
Related publications
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Cancers
Cancer Research
Oncology
Evolving Therapy in Relapsed Myeloma
Cancer therapy & Oncology International Journal
Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design
Future Oncology
Medicine
Cancer Research
Oncology
Cost-Effectiveness of Adding Carfilzomib to Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma From a US Perspective
Journal of Medical Economics
Health Policy
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma
Core Evidence
Medicine
Reviews
References
Pharmacology
Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Cancer Science
Cancer Research
Medicine
Oncology
A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
